High<i>SLC20A1</i>Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers
Chotaro Onaga, Shoma Tamori, Hitomi Motomura, Ayaka Ozaki, Chika Matsuda, Izumi Matsuoka, Takuma Fujita, Yuka Nozaki, Yasushi Hara, Y. Kawano, Yohsuke Harada, Tsugumichi Sato, Yasunari Mano, Keiko Sato, Kazunori Akimoto
Abstract
BACKGROUND/AIM: SLC20A1 has been identified as a prognostic marker in ER+ breast cancer. However, the role of SLC20A1 expression in breast cancer subtypes other than the ER+ types remains unclear. MATERIALS AND METHODS: Genomics datasets were downloaded and analyzed, and the effect of SLC20A1 knockdown using targeted siRNA on cell viability and tumor-sphere formation was assessed. RESULTS: cells. These results suggest that SLC20A1 is involved in cancer progression and contributes to clinical outcomes in patients with ER+, claudin-low and basal-like breast cancers. CONCLUSION: SLC20A1 is a potential prognostic marker and therapeutic target in ER+, claudin-low and basal-like breast cancers.